Blueprint Medicines (BPMC) Misses Q3 EPS by 5c

Blueprint Medicines (NASDAQ: BPMC) reported Q3 EPS of ($0.96), $0.05 worse than the analyst estimate of ($0.91).

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.

You May Also Be Interested In

• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
• Ubiquiti (UI) Tops Q4 EPS by 25c, Beats on Revenue
• Nordson Corp. (NDSN) Tops Q3 EPS by 16c; Offers Guidance